Now, various drugs can be used for first-line treatment options in advanced lung cancer with ALK rearrangement, from the initial generation of crizotinib to the second generation of ceritinib, alectinib, and brigatinib, to the third generation of lorlatinib (6–10). Here, ALK is linked to lung cancer.